Annikki’s proprietary process produces high-value, non-toxic, bio-based alternatives to high-volume chemicals while minimizing waste and environmental consequences of chemical production. With its mild conversion process, Annikki can produce valuable products, at unsurpassed yields, with high-purity and low incidence of side reactions.Visit Website
Avalyn Pharmaceuticals is developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a fatal lung disease that causes more deaths per year than breast cancer. The company’s lead asset, pirfenidone (Aerodone™), has been reformulated for nebulization and has been granted orphan-drug designation by both US and European regulatory agencies.Visit Website
Immusoft has developed a methodology designed to use a patient’s immune cells to treat disease. Its propriety Immune System Programming (ISP™) technology reprograms B cells with the goal of treating diseases, including MPS-I (Mucopolysaccharidosis type I), a rare genetic lysosomal storage disease that is expected to be Immusoft’s first clinical application.Visit Website
Oncternal (NASDAQ: ONCT)
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. The company’s cutting-edge scientific approach is focused on targets that are uniquely expressed in cancer cells, resulting in highly targeted new therapies.Visit Website
Retrotope’s drug platform, deuterium stabilized PUFAs, aims to preserve and restore mitochondrial health in degenerative diseases including Parkinson’s, Alzheimer’s, and diabetic retinopathy, among others. The unique mechanism of this new category of drugs prevents cellular damage and recovers cellular function damaged by lipid peroxidation.Visit Website
selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. The company’s most advanced drug candidate, si-544, is a best-in-class Kv1.3 blocker for the treatment of autoimmune diseases.Visit Website
Telephus has developed a novel, monoclonal antibody for antibiotic-resistant staph infections. There is currently no reliable way to effectively prevent and treat bacterial infections related to implantable medical devices, and rates of infection following surgery are alarmingly high. Telephus’ therapy allows the native immune response to clear the infection and improves safety by reducing antibiotic drug interactions.
Soluventis Nanotherapeutics is a US-German biotechnology firm focused on the development of a proprietary Nanocarrier platform technology for the reliable systemic delivery of nucleic acids into virtually all tissues, including tumors and metastases. This technology enables the development of highly specific future RNA-based therapeutics.Visit Website
Treemera GmbH has developed a highly efficient and economical process to manufacture furandicarboxylicacid (FDCA), the building block for high purity PEF. PEF is a 100% recyclable bio-based polymer derived from plants. It has the potential to replace the plastic industry’s giant polyethylene terephthalate (PET), which is a durable material derived from conventional resources.
*GSV holds an indirect interest in Treemera GmbH through Annikki GmbH.Visit Website
VelosBio is a near-term, clinical-stage, biopharmaceutical company focused on a first-in-class antibody drug candidate (ADC) platform. The company was spun-out from Oncternal Therapeutics in 2017 and holds exclusive access and rights to UCSD/Oncternal ROR1-directed ADC/BiAbs portfolio.Visit Website
Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. Zavante’s lead product is a first-in-class injectable antibiotic to combat serious, life threatening infections, including those due to multi-drug resistant bacteria.Visit Website
RetroSense develops gene therapies designed to restore functional vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration (AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these degenerative conditions. RetroSense strives to provide the solution to this growing need.Visit Website